ES2956684T8 - Productos para la administración de compuestos terapéuticos/de diagnóstico al corazón - Google Patents

Productos para la administración de compuestos terapéuticos/de diagnóstico al corazón Download PDF

Info

Publication number
ES2956684T8
ES2956684T8 ES15825795T ES15825795T ES2956684T8 ES 2956684 T8 ES2956684 T8 ES 2956684T8 ES 15825795 T ES15825795 T ES 15825795T ES 15825795 T ES15825795 T ES 15825795T ES 2956684 T8 ES2956684 T8 ES 2956684T8
Authority
ES
Spain
Prior art keywords
heart
therapeutic
delivery
products
diagnostic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15825795T
Other languages
English (en)
Other versions
ES2956684T3 (es
Inventor
Daniele Catalucci
Michele Miragoli
Michele Iafisco
Anna Tampieri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consiglio Nazionale delle Richerche CNR
Istituto Nazionale per lAssicurazione contro gli Infortuni sul Lavoro INAIL
Original Assignee
Consiglio Nazionale delle Richerche CNR
Istituto Nazionale per lAssicurazione contro gli Infortuni sul Lavoro INAIL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale delle Richerche CNR, Istituto Nazionale per lAssicurazione contro gli Infortuni sul Lavoro INAIL filed Critical Consiglio Nazionale delle Richerche CNR
Application granted granted Critical
Publication of ES2956684T3 publication Critical patent/ES2956684T3/es
Publication of ES2956684T8 publication Critical patent/ES2956684T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15825795T 2014-12-22 2015-12-22 Productos para la administración de compuestos terapéuticos/de diagnóstico al corazón Active ES2956684T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20142207 2014-12-22
PCT/EP2015/080991 WO2016102576A1 (en) 2014-12-22 2015-12-22 Products for the delivery of therapeutic/diagnostic compounds to the heart

Publications (2)

Publication Number Publication Date
ES2956684T3 ES2956684T3 (es) 2023-12-26
ES2956684T8 true ES2956684T8 (es) 2024-03-27

Family

ID=52574296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15825795T Active ES2956684T3 (es) 2014-12-22 2015-12-22 Productos para la administración de compuestos terapéuticos/de diagnóstico al corazón

Country Status (15)

Country Link
US (1) US10729660B2 (es)
EP (1) EP3236947B1 (es)
JP (1) JP6781712B2 (es)
KR (1) KR102532139B1 (es)
CN (1) CN107205934B (es)
AU (1) AU2015370986B2 (es)
BR (1) BR112017013476B1 (es)
CA (1) CA2971519C (es)
ES (1) ES2956684T3 (es)
IL (1) IL253141B (es)
MX (1) MX379568B (es)
PL (1) PL3236947T3 (es)
RU (1) RU2721778C2 (es)
SG (1) SG11201705128VA (es)
WO (1) WO2016102576A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971569B (zh) * 2018-02-19 2023-04-25 布鲁克法国股份公司 多孔基质中的核自旋超极化
IT201800006753A1 (it) * 2018-06-28 2019-12-28 Calcio fosfato amorfo stabilizzato dopato con ioni fluoruro e un procedimento per produrlo
CN111870582B (zh) * 2020-06-28 2022-03-18 苏州天微肽生物医药科技有限公司 正硅酸乙酯-利拉鲁肽复合微球制剂及其制备方法和应用
IT202000021292A1 (it) * 2020-09-09 2022-03-09 Consiglio Nazionale Ricerche Composizione in forma di polvere a base di microparticelle incorporanti nanoparticelle per la veicolazione di composti terapeutici/diagnostici

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
AU2004212944B2 (en) * 2003-02-14 2008-08-21 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
US7595322B2 (en) * 2003-03-27 2009-09-29 Cytokinetics, Inc. Heterocyclic sulfonamides as modulators of cardiac sarcomeres
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2309991B1 (en) * 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2010085651A1 (en) 2009-01-23 2010-07-29 The Penn State Research Foundation In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
ES2557183B1 (es) * 2014-07-21 2016-11-03 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de obtención de nanopartículas de fosfato de calcio amorfo recubiertas de citrato y dopadas con flúor

Also Published As

Publication number Publication date
US10729660B2 (en) 2020-08-04
JP6781712B2 (ja) 2020-11-04
CN107205934B (zh) 2023-06-30
PL3236947T3 (pl) 2023-12-27
EP3236947C0 (en) 2023-06-28
BR112017013476B1 (pt) 2023-02-07
MX379568B (es) 2025-03-11
AU2015370986A1 (en) 2017-07-27
EP3236947A1 (en) 2017-11-01
AU2015370986B2 (en) 2021-02-04
IL253141B (en) 2022-04-01
RU2721778C2 (ru) 2020-05-22
ES2956684T3 (es) 2023-12-26
KR102532139B1 (ko) 2023-05-12
RU2017126093A3 (es) 2019-06-06
JP2018505211A (ja) 2018-02-22
RU2017126093A (ru) 2019-01-24
IL253141A0 (en) 2017-08-31
SG11201705128VA (en) 2017-07-28
CA2971519A1 (en) 2016-06-30
MX2017008330A (es) 2018-04-24
KR20170108954A (ko) 2017-09-27
CA2971519C (en) 2023-04-11
BR112017013476A2 (pt) 2018-01-09
US20170348245A1 (en) 2017-12-07
WO2016102576A1 (en) 2016-06-30
CN107205934A (zh) 2017-09-26
EP3236947B1 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
IL256175A (en) Using exosomes to treat the disease
PT3212233T (pt) Terapia combinada para o tratamento de doenças
HUE054389T2 (hu) Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
IL247452A0 (en) Compounds for treatment of complement mediated disorders
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
SG11201704212SA (en) Human antibodies to influenza hemagglutinin
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
ZA201800832B (en) Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease
HUE062482T2 (hu) Lactobacillus reuteri- és citráttartalmú készítmény gyógyászati felhasználásra
FR3035320B1 (fr) Distributeur de medicaments a un patient
EP2946777C0 (en) MEDICINE FOR THE TREATMENT OF A NEUROPATHIC DISEASE
LT3052466T (lt) Ksantohumolio paruošimo būdas
IL253141A0 (en) Products for administering medical or diagnostic preparations to the heart
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
IL259381B (en) Mirabegron for the treatment of retinal diseases
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
DK3148582T3 (da) Antiretroviralt lægemiddel målrettet mod human endogen retrovirus
DK3107568T3 (da) Formuleringer til indgivelse til tyndtarmen
GB201410407D0 (en) Treatment of chagas disease